{
    "hands_on_practices": [
        {
            "introduction": "The initial assessment of a patient with acute pharyngitis represents a classic problem in clinical reasoning, where a physician must weigh the probability of Group A Streptococcus (GAS) infection against other causes. This exercise demonstrates how to formalize this process using Bayesian inference. By combining a known pre-test probability (the local prevalence of GAS) with the diagnostic evidence provided by clinical signs, encapsulated here by the Centor score, you can calculate a more accurate posterior probability of disease, a cornerstone of evidence-based practice .",
            "id": "4695178",
            "problem": "A clinician evaluating an adult with acute pharyngitis is concerned about Group A Streptococcus (GAS; Streptococcus pyogenes) infection due to the potential for immune-mediated sequelae such as acute rheumatic fever and post-streptococcal glomerulonephritis. The patient has a Centor score of $4$, meaning all four criteria are present: tonsillar exudates, tender anterior cervical lymphadenopathy, history of fever, and absence of cough. Assume a pre-test prevalence (interpreted as pre-test probability) of GAS in the community of $0.30$. Under the assumption that, conditional on disease status, the Centor criteria contribute independently to the diagnostic evidence, use Bayes theorem and the definition of the likelihood ratio to compute the posterior probability of GAS infection when all four criteria are positive. For the individual likelihood ratios (positive) of each criterion, use the following values, which are consistent with meta-analytic estimates in adult populations:\n\n- Tonsillar exudates: $\\text{LR}^{+} = 2.5$\n- Tender anterior cervical lymphadenopathy: $\\text{LR}^{+} = 1.7$\n- History of fever: $\\text{LR}^{+} = 1.5$\n- Absence of cough: $\\text{LR}^{+} = 1.3$\n\nExpress your final answer as a decimal probability and round to four significant figures. Do not use a percentage sign.",
            "solution": "The problem is valid. It is a well-posed application of Bayesian inference in a standard clinical diagnostic scenario, using established concepts such as pre-test probability and likelihood ratios. All necessary data and assumptions are provided.\n\nThe objective is to calculate the posterior probability of a Group A Streptococcus (GAS) infection given that all four Centor criteria are present. We will use Bayes' theorem, conveniently expressed in its odds-likelihood form.\n\nLet $D$ be the event that the patient has a GAS infection. The problem provides the pre-test prevalence, which we interpret as the pre-test probability $P(D)$.\n$$P(D) = 0.30$$\nThe pre-test odds of infection, $O(D)$, are given by the ratio of the probability of the event to the probability of its complement:\n$$O(D) = \\frac{P(D)}{1 - P(D)}$$\nSubstituting the given value:\n$$O(D) = \\frac{0.30}{1 - 0.30} = \\frac{0.30}{0.70} = \\frac{3}{7}$$\nLet $E$ denote the collected evidence, which is that all four Centor criteria are positive. We are tasked with finding the posterior probability of disease given this evidence, $P(D|E)$.\n\nBayes' theorem in odds form states that the posterior odds are the product of the prior odds and the likelihood ratio (LR) of the evidence:\n$$O(D|E) = O(D) \\times \\text{LR}^{+}(E)$$\nHere, $\\text{LR}^{+}(E)$ is the positive likelihood ratio for the combined set of evidence $E$.\n\nThe problem states that, conditional on disease status, the Centor criteria contribute independently. This critical assumption allows us to calculate the combined likelihood ratio by multiplying the individual likelihood ratios for each positive criterion. The given individual positive likelihood ratios ($\\text{LR}^{+}$) are:\n- Tonsillar exudates: $\\text{LR}^{+}_{1} = 2.5$\n- Tender anterior cervical lymphadenopathy: $\\text{LR}^{+}_{2} = 1.7$\n- History of fever: $\\text{LR}^{+}_{3} = 1.5$\n- Absence of cough: $\\text{LR}^{+}_{4} = 1.3$\n\nThe combined likelihood ratio is therefore:\n$$\\text{LR}^{+}(E) = \\text{LR}^{+}_{1} \\times \\text{LR}^{+}_{2} \\times \\text{LR}^{+}_{3} \\times \\text{LR}^{+}_{4}$$\n$$\\text{LR}^{+}(E) = 2.5 \\times 1.7 \\times 1.5 \\times 1.3$$\nPerforming the multiplication:\n$$\\text{LR}^{+}(E) = 8.2875$$\nNow we can calculate the posterior odds of infection:\n$$O(D|E) = O(D) \\times \\text{LR}^{+}(E) = \\frac{3}{7} \\times 8.2875$$\n$$O(D|E) = \\frac{24.8625}{7} \\approx 3.5517857$$\nFinally, we convert the posterior odds back to a probability using the relationship:\n$$P(D|E) = \\frac{O(D|E)}{1 + O(D|E)}$$\nSubstituting the value for the posterior odds:\n$$P(D|E) = \\frac{\\frac{24.8625}{7}}{1 + \\frac{24.8625}{7}} = \\frac{24.8625}{7 + 24.8625} = \\frac{24.8625}{31.8625}$$\nCalculating the numerical value:\n$$P(D|E) \\approx 0.780305...$$\nThe problem requires the answer to be rounded to four significant figures. The fifth significant figure is $0$, so we round down.\n$$P(D|E) \\approx 0.7803$$\nThis is the posterior probability of the patient having GAS pharyngitis, given a Centor score of $4$ and the specified pre-test probability and likelihood ratios.",
            "answer": "$$\\boxed{0.7803}$$"
        },
        {
            "introduction": "With the advent of highly sensitive diagnostic tools like Nucleic Acid Amplification Tests (NAATs), a positive result for *Streptococcus pyogenes* does not always signify etiologic infection; it may instead reflect asymptomatic carriage. This practice delves into this critical diagnostic challenge, requiring a more sophisticated application of Bayes' theorem to differentiate true infection from mere colonization . Mastering this allows for more precise clinical decision-making, ensuring that antibiotics are directed at true pathogens while avoiding unnecessary treatment of carriers.",
            "id": "4695182",
            "problem": "A clinical decision problem in infectious diseases concerns whether a positive throat swab for Streptococcus pyogenes truly reflects etiologic infection or merely carriage in a patient whose sore throat is due to another cause. Consider adult patients presenting with acute pharyngitis in a setting where the following pretest state prevalences are well-characterized: the proportion with true Streptococcus pyogenes pharyngitis is $p_{I} = 0.22$, the proportion with viral pharyngitis and concurrent asymptomatic Streptococcus pyogenes carriage is $p_{C} = 0.12$, and the remainder $p_{N} = 1 - p_{I} - p_{C}$ have neither Streptococcus pyogenes infection nor carriage. A single throat swab is tested by a Nucleic Acid Amplification Test (NAAT), which detects the presence of Streptococcus pyogenes genetic material. The probability that the NAAT is positive given true infection (reflecting higher organism burden) is $s_{I} = 0.93$, the probability it is positive given carriage (lower organism burden) is $s_{C} = 0.70$, and the probability it is positive in those without carriage (the false-positive rate, reflecting a specificity of $0.97$) is $f_{N} = 0.03$. Using only fundamental definitions of sensitivity, specificity, and prevalence, together with Bayesâ€™ theorem, derive from first principles the posterior probability that a positive NAAT indicates true Streptococcus pyogenes infection (etiologic pharyngitis) rather than carriage. Express your final answer as a decimal and round to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in clinical epidemiology, well-posed with a complete and consistent set of data, and objective in its formulation. It represents a classic application of Bayes' theorem to medical diagnostics, a non-trivial and meaningful problem.\n\nThe problem asks for the posterior probability that a patient with a positive Nucleic Acid Amplification Test (NAAT) result has a true *Streptococcus pyogenes* infection, as opposed to being an asymptomatic carrier or having a false-positive result. This is the positive predictive value of the test for true infection.\n\nLet us define the following events:\n- $I$: The patient has a true *Streptococcus pyogenes* infection (etiologic pharyngitis).\n- $C$: The patient is an asymptomatic carrier of *Streptococcus pyogenes* (with pharyngitis from another cause, e.g., viral).\n- $N$: The patient has neither infection nor carriage.\n- $T^{+}$: The NAAT result is positive.\n\nThe problem provides the following prior probabilities (prevalences) for these three mutually exclusive and exhaustive states:\n- The probability of true infection, $P(I) = p_{I} = 0.22$.\n- The probability of asymptomatic carriage, $P(C) = p_{C} = 0.12$.\n- The probability of neither infection nor carriage, $P(N) = p_{N} = 1 - p_{I} - p_{C} = 1 - 0.22 - 0.12 = 0.66$.\n\nThe problem also provides the conditional probabilities of a positive test given each state. These are related to the sensitivity and specificity of the test for detecting *Streptococcus pyogenes* material.\n- The probability of a positive test given true infection is $P(T^{+} | I) = s_{I} = 0.93$. This can be considered the sensitivity of the test for etiologic infection.\n- The probability of a positive test given carriage is $P(T^{+} | C) = s_{C} = 0.70$.\n- The probability of a positive test given neither infection nor carriage is $P(T^{+} | N) = f_{N} = 0.03$. This represents the false-positive rate, which is $1$ minus the test's specificity. The problem states the specificity is $0.97$, so $f_{N} = 1 - 0.97 = 0.03$, which is consistent.\n\nWe are asked to find the posterior probability of true infection given a positive test result, which is denoted as $P(I | T^{+})$. According to Bayes' theorem, this is given by:\n$$P(I | T^{+}) = \\frac{P(T^{+} | I) P(I)}{P(T^{+})}$$\n\nThe numerator is the joint probability of having a true infection and testing positive. We can calculate it directly from the given values:\n$$P(T^{+} | I) P(I) = s_{I} \\times p_{I} = 0.93 \\times 0.22 = 0.2046$$\n\nThe denominator, $P(T^{+})$, is the overall probability of obtaining a positive test result across the entire patient population. To find this, we use the law of total probability, summing the probabilities of a positive test over all possible patient states ($I$, $C$, and $N$):\n$$P(T^{+}) = P(T^{+} | I)P(I) + P(T^{+} | C)P(C) + P(T^{+} | N)P(N)$$\n\nSubstituting the given values into this expression:\n$$P(T^{+}) = (s_{I} \\times p_{I}) + (s_{C} \\times p_{C}) + (f_{N} \\times p_{N})$$\n$$P(T^{+}) = (0.93 \\times 0.22) + (0.70 \\times 0.12) + (0.03 \\times 0.66)$$\n\nLet's calculate each term:\n- The contribution from true infections: $0.93 \\times 0.22 = 0.2046$\n- The contribution from carriers: $0.70 \\times 0.12 = 0.0840$\n- The contribution from false positives: $0.03 \\times 0.66 = 0.0198$\n\nSumming these contributions gives the total probability of a positive test:\n$$P(T^{+}) = 0.2046 + 0.0840 + 0.0198 = 0.3084$$\n\nNow we can substitute the values for the numerator and the denominator back into the Bayes' theorem formula for $P(I | T^{+})$:\n$$P(I | T^{+}) = \\frac{0.2046}{0.3084}$$\n\nPerforming the division gives the numerical value:\n$$P(I | T^{+}) \\approx 0.6634241245...$$\n\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures are $6$, $6$, $3$, and $4$. The fifth digit is $2$, so we round down.\n$$P(I | T^{+}) \\approx 0.6634$$\n\nThus, for a patient in this clinical setting, a positive NAAT for *Streptococcus pyogenes* corresponds to a $66.34\\%$ probability of having a true, etiologic infection.",
            "answer": "$$\\boxed{0.6634}$$"
        },
        {
            "introduction": "Beyond individual patient care, effective management of infectious diseases requires sound public health and clinical policies. This capstone exercise shifts the focus from individual diagnosis to a systems-level analysis, comparing two competing strategies for managing acute pharyngitis: empirical treatment versus a test-and-treat approach . By constructing a model to compute the incremental cost-effectiveness ratio (ICER), you will learn to integrate epidemiological data, test performance characteristics, and economic costs to evaluate and justify large-scale health interventions.",
            "id": "4695353",
            "problem": "A community health clinic must choose between two management strategies for patients presenting with acute pharyngitis, in a setting where Group A beta-hemolytic Streptococcus (Streptococcus pyogenes) is prevalent and the population has a nontrivial risk of developing Acute Rheumatic Fever (ARF) after untreated streptococcal pharyngitis. The decision is constrained by costs and clinical performance characteristics of diagnostic testing. The clinic is comparing Strategy E (empirical penicillin therapy for all patients) versus Strategy R (Rapid Antigen Detection Test (RADT) for all patients with antibiotic treatment only for RADT-positive results). Assume all treated patients receive penicillin promptly, adherence is sufficient that the stated risk reduction applies, and there is no backup throat culture. Use the following scientifically plausible parameters:\n\n- Prevalence of Streptococcus pyogenes among symptomatic presentations: $p = 0.35$.\n- RADT sensitivity: $s_{R} = 0.85$.\n- RADT specificity: $\\text{sp}_{R} = 0.95$.\n- Risk of Acute Rheumatic Fever (ARF) after untreated Streptococcus pyogenes pharyngitis: $r_{\\text{ARF}} = 0.005$.\n- Relative risk reduction of ARF when appropriately treated with penicillin: $\\text{RRR} = 0.80$.\n- Cost of penicillin course per patient: $c_{A} = 6$ dollars.\n- Probability of anaphylaxis requiring emergency care per penicillin course: $r_{\\text{ana}} = 2 \\times 10^{-4}$.\n- Cost of anaphylaxis event: $c_{\\text{ana}} = 10000$ dollars.\n- Cost of RADT per patient: $c_{R} = 12$ dollars.\n- Direct medical cost of an ARF event: $c_{\\text{ARF}} = 15000$ dollars.\n\nEffectiveness is defined as the expected Acute Rheumatic Fever cases avoided per patient relative to a baseline of untreated streptococcal disease; however, for the incremental cost-effectiveness ratio (ICER) between Strategy E and Strategy R, use the standard definition: $\\text{ICER} = \\frac{\\Delta \\text{Cost}}{\\Delta \\text{Effectiveness}}$, where $\\Delta \\text{Cost}$ and $\\Delta \\text{Effectiveness}$ are computed for Strategy E relative to Strategy R.\n\nTasks:\n1. Derive the expected probability of receiving antibiotics under Strategy R using the definitions of sensitivity and specificity and the prevalence $p$.\n2. From first principles using sensitivity, specificity, and prevalence, compute the expected probability of Acute Rheumatic Fever per patient under Strategy E and Strategy R.\n3. Compute the expected total cost per patient under Strategy E and Strategy R, including test costs (if any), antibiotic costs, expected anaphylaxis costs, and expected ARF costs.\n4. Compute the incremental cost-effectiveness ratio (ICER) of Strategy E relative to Strategy R, expressed in dollars per ARF case avoided.\n\nRound your final ICER to four significant figures. Express the final ICER in dollars per ARF case avoided.",
            "solution": "This problem requires a cost-effectiveness analysis comparing two strategies for managing acute pharyngitis: Strategy E (Empirical treatment for all) and Strategy R (RADT test, treat if positive). We need to calculate the incremental cost-effectiveness ratio (ICER) of Strategy E relative to Strategy R.\n\nFirst, let's summarize the parameters:\n- Prevalence of Strep, $p = 0.35$\n- RADT sensitivity, $s_R = 0.85$\n- RADT specificity, $sp_R = 0.95$\n- Risk of ARF if untreated, $r_{\\text{ARF}} = 0.005$\n- Relative risk reduction from treatment, $\\text{RRR} = 0.80$\n- Cost of antibiotics, $c_A = 6$\n- Cost of RADT, $c_R = 12$\n- Cost of ARF event, $c_{\\text{ARF}} = 15000$\n- Risk of anaphylaxis, $r_{\\text{ana}} = 2 \\times 10^{-4}$\n- Cost of anaphylaxis, $c_{\\text{ana}} = 10000$\n\nThe risk of ARF if treated is $r_{\\text{ARF, treated}} = r_{\\text{ARF}} \\times (1 - \\text{RRR}) = 0.005 \\times (1 - 0.80) = 0.001$.\n\n**Step 1: Calculate Probabilities for Strategy R**\n\nThe probability of receiving antibiotics under Strategy R is the probability of a positive RADT test.\n$P(\\text{Treat}_R) = P(\\text{RADT+}) = P(\\text{RADT+}|\\text{Strep})P(\\text{Strep}) + P(\\text{RADT+}|\\text{No Strep})P(\\text{No Strep})$\n$P(\\text{Treat}_R) = s_R \\cdot p + (1 - sp_R) \\cdot (1 - p)$\n$P(\\text{Treat}_R) = (0.85 \\cdot 0.35) + (0.05 \\cdot 0.65) = 0.2975 + 0.0325 = 0.33$\n\n**Step 2: Calculate Expected ARF Probability per Patient**\n\n**Strategy E (Empirical):** All patients with Strep are treated.\n$P(\\text{ARF}_E) = p \\times r_{\\text{ARF, treated}} = 0.35 \\times 0.001 = 0.00035$\n\n**Strategy R (Test and Treat):** Only Strep patients who test positive (True Positives, TP) are treated. Strep patients who test negative (False Negatives, FN) are untreated.\n$P(\\text{TP}) = P(\\text{Strep} \\cap \\text{RADT+}) = s_R \\cdot p = 0.85 \\times 0.35 = 0.2975$\n$P(\\text{FN}) = P(\\text{Strep} \\cap \\text{RADT-}) = (1 - s_R) \\cdot p = 0.15 \\times 0.35 = 0.0525$\nThe probability of ARF is the sum of risks from treated and untreated Strep cases:\n$P(\\text{ARF}_R) = (P(\\text{TP}) \\times r_{\\text{ARF, treated}}) + (P(\\text{FN}) \\times r_{\\text{ARF}})$\n$P(\\text{ARF}_R) = (0.2975 \\times 0.001) + (0.0525 \\times 0.005)$\n$P(\\text{ARF}_R) = 0.0002975 + 0.0002625 = 0.00056$\n\n**Step 3: Calculate Expected Total Cost per Patient**\n\nThe total cost per patient is the sum of test costs, antibiotic costs, expected anaphylaxis costs, and expected ARF costs.\nExpected Anaphylaxis Cost per treated patient = $r_{\\text{ana}} \\times c_{\\text{ana}} = 2 \\times 10^{-4} \\times 10000 = 2$ dollars.\n\n**Cost of Strategy E:**\n- Test cost: $0\n- Antibiotic cost: $1 \\times c_A = 6$\n- Anaphylaxis cost: $1 \\times (\\text{Expected Anaphylaxis Cost per treated patient}) = 2$\n- ARF cost: $P(\\text{ARF}_E) \\times c_{\\text{ARF}} = 0.00035 \\times 15000 = 5.25$\n$\\text{Cost}_E = 0 + 6 + 2 + 5.25 = 13.25$ dollars.\n\n**Cost of Strategy R:**\n- Test cost: $1 \\times c_R = 12$\n- Antibiotic cost: $P(\\text{Treat}_R) \\times c_A = 0.33 \\times 6 = 1.98$\n- Anaphylaxis cost: $P(\\text{Treat}_R) \\times (\\text{Expected Anaphylaxis Cost per treated patient}) = 0.33 \\times 2 = 0.66$\n- ARF cost: $P(\\text{ARF}_R) \\times c_{\\text{ARF}} = 0.00056 \\times 15000 = 8.40$\n$\\text{Cost}_R = 12 + 1.98 + 0.66 + 8.40 = 23.04$ dollars.\n\n**Step 4: Calculate ICER**\n\nThe ICER is defined as $\\frac{\\Delta \\text{Cost}}{\\Delta \\text{Effectiveness}}$.\n$\\Delta \\text{Cost} = \\text{Cost}_E - \\text{Cost}_R = 13.25 - 23.04 = -9.79$ dollars.\n\nEffectiveness is defined as ARF cases avoided per patient relative to a no-treatment baseline.\nBaseline ARF cases (if no one is treated) = $p \\times r_{\\text{ARF}} = 0.35 \\times 0.005 = 0.00175$.\nEffectiveness$_E$ = Cases avoided under E = Baseline ARF - $P(\\text{ARF}_E) = 0.00175 - 0.00035 = 0.00140$\nEffectiveness$_R$ = Cases avoided under R = Baseline ARF - $P(\\text{ARF}_R) = 0.00175 - 0.00056 = 0.00119$\n\n$\\Delta \\text{Effectiveness} = \\text{Effectiveness}_E - \\text{Effectiveness}_R = 0.00140 - 0.00119 = 0.00021$ ARF cases avoided.\n\n$\\text{ICER} = \\frac{\\Delta \\text{Cost}}{\\Delta \\text{Effectiveness}} = \\frac{-9.79}{0.00021} \\approx -46619.0476$\n\nRounding to four significant figures, we get:\n$\\text{ICER} = -46620$ dollars per ARF case avoided.\n\nThe negative ICER indicates that Strategy E is dominant: it is both more effective (avoids more ARF cases) and less costly than Strategy R under these assumptions.",
            "answer": "$$\\boxed{-46620}$$"
        }
    ]
}